Skip to main content
. 2023 Jan 23;41(16):2893–2903. doi: 10.1200/JCO.22.02823

FIG 2.

FIG 2.

Efficacy of tarlatamab in patients with SCLC. (A) Kaplan-Meier curve of PFS for patients whose data cutoff date is at least 9 weeks after the first dose date (N = 107). (B) Kaplan-Meier curve of OS for patients whose data cutoff date is at least 9 weeks after the first dose date (N = 107). OS, overall survival; PFS, progression-free survival; SCLC, small-cell lung cancer.